Verseon Corp

FREMONT, CA · CIK 0001348948 · Biotech · Private

AI-driven drug design and development platform for computational drug discovery

verseon.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$25M
7 Form D · Apr 2019
89 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$5,832,264
Private capital raised· 1 of 5 same dayForm D · SEC$259,573
Private capital raised· 2 of 5 same dayForm D · SEC$11,808,858
Private capital raised· 3 of 5 same dayForm D · SEC$451,000
Private capital raised· 4 of 5 same dayForm D · SEC$6,488,600
Private capital raised· 5 of 5 same dayForm D · SEC$69,827
Private capital raisedForm D · SEC$101,400
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2460Eidos Therapeutics—$26M
2461Expesicor Inc——
2462Actym Therapeutics, Inc.—$25M
2463Verseon Corp—$25M
2464Pharmazz, Inc.—$25M
2465Abzena plc—$4.3M
2466CURADEL SURGICAL INNOVATIONS, INC.—$24M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 5 related persons
  • Eniko FodorDirector · Executive Officer
  • Thomas HechtDirector
  • Sangtae KimDirector
  • David KitaExecutive Officer
  • Adityo PrakashDirector · Executive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.